331 related articles for article (PubMed ID: 34706172)
1. Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.
Brightling CE; Nair P; Cousins DJ; Louis R; Singh D
N Engl J Med; 2021 Oct; 385(18):1669-1679. PubMed ID: 34706172
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
6. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab in persistent asthma with elevated eosinophil levels.
Wenzel S; Ford L; Pearlman D; Spector S; Sher L; Skobieranda F; Wang L; Kirkesseli S; Rocklin R; Bock B; Hamilton J; Ming JE; Radin A; Stahl N; Yancopoulos GD; Graham N; Pirozzi G
N Engl J Med; 2013 Jun; 368(26):2455-66. PubMed ID: 23688323
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Rabe KF; Nair P; Brusselle G; Maspero JF; Castro M; Sher L; Zhu H; Hamilton JD; Swanson BN; Khan A; Chao J; Staudinger H; Pirozzi G; Antoni C; Amin N; Ruddy M; Akinlade B; Graham NMH; Stahl N; Yancopoulos GD; Teper A
N Engl J Med; 2018 Jun; 378(26):2475-2485. PubMed ID: 29782224
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
Bacharier LB; Maspero JF; Katelaris CH; Fiocchi AG; Gagnon R; de Mir I; Jain N; Sher LD; Mao X; Liu D; Zhang Y; Khan AH; Kapoor U; Khokhar FA; Rowe PJ; Deniz Y; Ruddy M; Laws E; Patel N; Weinreich DM; Yancopoulos GD; Amin N; Mannent LP; Lederer DJ; Hardin M;
N Engl J Med; 2021 Dec; 385(24):2230-2240. PubMed ID: 34879449
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P;
N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
14. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.
Oh CK; Leigh R; McLaurin KK; Kim K; Hultquist M; Molfino NA
Respir Res; 2013 Sep; 14(1):93. PubMed ID: 24050312
[TBL] [Abstract][Full Text] [Related]
16. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
Wechsler ME; Ruddy MK; Pavord ID; Israel E; Rabe KF; Ford LB; Maspero JF; Abdulai RM; Hu CC; Martincova R; Jessel A; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
N Engl J Med; 2021 Oct; 385(18):1656-1668. PubMed ID: 34706171
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
[TBL] [Abstract][Full Text] [Related]
20. A Phase 2a Study of DP
Asano K; Sagara H; Ichinose M; Hirata M; Nakajima A; Ortega H; Tohda Y
J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1275-1283.e1. PubMed ID: 31778823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
